| FENNEC PHARMACEUT. |
| Kanada |
| Gesundheit |
| CA31447P1009 / A12A5F |
| RV41 (Frankfurt) / FENC (NASDAQ) |
| FRA:RV41, ETR:RV41, RV41:GR, NASDAQ:FENC |
| - |
| https://fennecpharma.com/ |
|
Fennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer. The company's flagship product candidate, Pedmark, is designed to reduce ototoxicity, or he..
>Volltext.. |
| 178.26 Mio. EUR |
| 146.93 Mio. EUR |
| 39.42 Mio. EUR |
| -5.95 Mio. EUR |
| -8.91 Mio. EUR |
| -0.3 EUR |
| - |
| 31.91 Mio. EUR |
| -12.75 Mio. EUR |
| 3.5 |
| -11.14% |
| -3404.59% |
| - |
| - |
| - |
| FENNEC |
| 31.03.26 |